Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 24th Preview)
-
Regenxbio’s Hunter gene therapy faces renewed FDA action
FDA has placed Regenxbio’s Hunter syndrome gene therapy program under another clinical hold after MRI findings involving asymptomatic spine changes, derailing the company’s plan to refile for approval. Regenxbio linked the hold to spine MRI results and said it no longer expects to file in the near term. Separately, Regenxbio disclosed that investigators detected masses on the spines of five patients who received its Hunter syndrome treatment—marking the program’s second clinical hold this year. The company said the patients did not have symptoms related to the masses. The latest pause follows an earlier signal tied to a related AAV gene therapy case, underscoring heightened scrutiny of AAV-associated safety signals. For investors and clinicians, the holds extend uncertainty around the timing and feasibility of regulatory re-engagement for MPS II.
-
Capricor deramiocel reviews extended as agency requests more data
FDA has delayed its decision date for Capricor Therapeutics’ deramiocel, extending the agency’s review of the Duchenne muscular dystrophy program after the company submitted updated information for a refined indication. The move pushes the PDUFA timeline further as FDA evaluates additional datasets. In parallel, FDA also extended review of Capricor’s cell therapy and indicated it is focusing on an updated application with a more targeted label. Capricor’s deramiocel is based on the company’s cardiosphere-derived cell platform, which is being positioned for specific patient subgroups. For Capricor and the broader cell-therapy field, the extension signals continued regulatory focus on clinical evidence strength and label specificity, especially for cell products seeking expanded or more niche indications.
-
Ambros completes Werewolf merger to fund pivotal CRPS-1 path
Werewolf Therapeutics and Ambros Therapeutics agreed to merge, with an oversubscribed $150 million private placement and a plan to advance neridronate toward a potential first FDA approval for complex regional pain syndrome type 1. The combined company will operate as Ambros Therapeutics and is expected to list on Nasdaq under ticker AMBX once the deal closes. The financing is expected to fund operations through topline data from the pivotal CRPS-RISE Phase III trial (NCT07210515), creating a runway aligned to a near-term clinical readout. Neridronate has already received Breakthrough Therapy, Fast Track, and Orphan Drug designations. The deal structure—using a public listing vehicle rather than a traditional IPO—is increasingly common for smaller biotechs seeking capital and market access without an initial public offering.
-
WHO opens prequalification pathway for targeted NGS and TB IGRAs
WHO has officially opened its prequalification pathway for targeted next-generation sequencing (tNGS) and interferon gamma release assays (IGRAs) for tuberculosis in vitro diagnostics. The initiative is designed to support independent assessment of test safety, quality, and performance for procurement by countries and international groups. WHO said the process will proceed after establishment of policies for different testing categories across diseases. During the launch webinar, WHO also indicated it has listed five IGRAs and three tNGS tests as first-in-class in its policy documents, while clarifying that inclusion does not guarantee prequalification. Applications for WHO prequalification assessment of IGRA and tNGS assays will open Sept. 1, 2026, with abridged dossier options available for developers meeting regulatory-clearance and ISO criteria. The move may accelerate global uptake of newer TB diagnostic modalities beyond traditional platforms.
-
TwinStrand wins major duplex sequencing patent damages vs Guardant
A US District Court for the District of Delaware ordered Guardant Health to pay roughly $245 million in damages, royalties, and interest to TwinStrand Biosciences and the University of Washington over duplex sequencing patents. The court’s ruling includes supplemental damages on top of an earlier $83.4 million damages finding from a 2023 decision. The judgment also calls for an ongoing 6% royalty rate tied to 11 products and requires quarterly US sales accounting for the covered assays and services, including Guardant360 and related LUNAR-1 testing. TwinStrand and UW originally sued in 2021 alleging willful infringement. While Guardant has indicated it is preparing an appeal and continues to challenge patent validity through PTAB, the decision reinforces IP leverage around duplex consensus sequencing—an approach central to lowering sequencing error rates in clinical genomics.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.